Back to top

Tale of the Tape

Zacks Equity Research

Why Impax Laboratories (IPXL) Could Be Positioned for a Slump
November 21, 2016

IPXL ADMS

Trades from $3

Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio.

One such stock that you may want to consider dropping is Impax Laboratories Inc. (IPXL - Free Report) , which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. A Zacks Rank #5 (Strong Sell) further confirms weakness in IPXL.

A key reason for this move has been the negative trend in earnings estimate revisions. For the full year, we have seen 7 estimates moving down in the past 30 days, compared with no upward revision. This trend has caused the consensus estimate to trend lower, going from $1.60 a share a month ago to its current level of $1.17.

Also, for the current quarter, Impax Laboratorieshas seen 5 downward estimate revisions versus no revision in the opposite direction, dragging the consensus estimate down to 21 cents a share from 55 cents over the past 30 days.  

The stock also has seen some pretty dismal trading lately, as the share price has dropped 33.8% in the past month.

IMPAX LABORATRS Price and Consensus

IMPAX LABORATRS Price and Consensus | IMPAX LABORATRS Quote

So it may not be a good decision to keep this stock in your portfolio anymore, at least if you don’t have a long time horizon to wait.

If you are still interested in the Medical-Generic Drugs industry, you may instead consider a better-ranked stock - Adamas Pharmaceuticals, Inc. (ADMS - Free Report) . The stock currently holds a Zacks Rank #2 (Buy) and may be a better selection at this time. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Zacks’ Best Private Investment Ideas

While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.

Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Click here for Zacks' private trades >>